Phase 2b/3 clinical trial for ABX-002
Latest Information Update: 26 Jul 2024
At a glance
- Drugs ABX-002 (Primary)
- Indications Adrenomyeloneuropathy
- Focus Adverse reactions; Registrational
- Sponsors Autobahn Therapeutics
- 24 Jul 2024 According to an Autobahn Therapeutics media release, company today announced closing of an oversubscribed $100 million series C financing led by Newpath partners and proceeds from series C will be used to commence two Phase 2 clinical trials for ABX-002.
- 09 Dec 2020 New trial record
- 01 Dec 2020 According to an Autobahn Therapeutics media release, As part of the meeting, FDA aligned the companys proposal to conduct a single Phase 2b/3 adaptive trial to support a potential future registration of ABX-002.